News & Media
Regulatory news, research developments, expert commentary and press coverage relevant to topical finasteride and male pattern hair loss.
MHRA strengthens warnings on finasteride psychiatric and sexual side effects
The UK regulator's Drug Safety Update reiterates expectations for prescribers and pharmacists when initiating finasteride, including in topical formulations dispensed by registered providers.
Phase III trial reports non-inferiority of topical finasteride spray vs oral 1 mg
Piraccini et al. (2022, JEADV) — multicentre, double-blind, double-dummy trial in male AGA. Topical 0.25% spray solution met non-inferiority for hair count with smaller systemic DHT impact.
Topical or oral finasteride: which is right for you?
Clinical comment from Sons UK, reviewed by Dr Knut Moe, on the practical considerations patients and prescribers weigh when choosing between the two routes.
Network meta-analysis ranks nonsurgical AGA therapies
Gupta et al. (2022, JAMA Dermatology) — indirect comparison of oral and topical finasteride, oral and topical minoxidil and several off-label interventions; useful for clinicians explaining relative efficacy.
EMA labelling updates on finasteride psychiatric and sexual side effects
The European Medicines Agency's review prompted strengthened patient information across EU-marketed finasteride products. Continues to shape how prescribers consent patients to topical and oral therapy.
UK online clinics expand access to topical finasteride combinations
MHRA-regulated providers including Sons (partnered with The Independent Pharmacy) now dispense topical finasteride and combination sprays under prescriber-led consultation in the UK.
"Treatment stacking" enters the mainstream hair-loss conversation
Long-form explainer on the increasingly common practice of combining finasteride (oral or topical), minoxidil, ketoconazole shampoo and adjunct therapies — and the evidence base behind each.
Pipeline watch: what we know about PP405 so far
Coverage of one of the more closely followed early-stage hair-loss candidates. Useful context for explaining where topical finasteride sits within the wider research landscape.
Pausing finasteride when planning a family: what prescribers advise
A patient-facing primer on stopping finasteride prior to conception, with the standard prescriber guidance applied in UK and Irish practice.
Press & media enquiries
For journalist enquiries, expert quotes or background briefings on Finjuve and topical finasteride, please contact the site team via the contact page. We can connect you with appropriately credentialed clinicians.